INTANGIBLE ASSETS (Tables)

9 Months Ended

Sep. 30, 2023

Intangible assets at September 30, 2023 and December 31, 2022 consist of the following:

	September 30, 2023						December 31, 2022
			Accumulated						Accumulated
	Cost		Amortization		Net		Cost		Amortization		Net
Trademark and other intangible rights related to Nabi-HB	$	4,100,046	$	3,709,565	$	390,481	$	4,100,046	$	3,270,276	$	829,770
Rights to intermediates		907,421		821,000		86,421		907,421		723,776		183,645
	$	5,007,467	$	4,530,565	$	476,902	$	5,007,467	$	3,994,052	$	1,013,415

Intangible Asset Future Aggregate Amortization Expense

All of the Company’s intangible assets were acquired in the Biotest Transaction. Amortization expense related to these intangible assets was $0.2 million for the three months ended September 30, 2023 and 2022, and $0.5 million for the nine months ended September 30, 2023 and 2022. Estimated future aggregate amortization expense is expected to be as follows:

Remainder of 2023		$	178,838
2024			298,064